Daniel Shoemaker

Daniel Shoemaker

Advisory Board Member @ Singular Genomics

About Daniel Shoemaker

Education and Expertise

Daniel Shoemaker holds a Ph.D. in biochemistry from Stanford University. Prior to that, he earned a B.S. in biochemistry from the University of California, Santa Barbara. His academic background has laid a strong foundation for his extensive work in biotechnology and biochemistry. His expertise encompasses the development of cell therapies, biotechnology innovations, and genomic analysis.

Title and Professional Role

Daniel Shoemaker currently serves as an advisory board member. His role includes providing strategic guidance and leveraging his vast experience in biotechnology to support organizational growth and innovation.

Leadership at Fate Therapeutics

From 2009 to 2021, Daniel Shoemaker served as the Chief Scientific Officer of Fate Therapeutics. In this capacity, he led innovation efforts to bring multiple induced pluripotent stem cell (iPSC) derived cell therapies to the clinic. His leadership was instrumental in advancing the company's scientific endeavors and clinical applications.

Tenure at ICx Biosystems

Daniel Shoemaker was the Chief Scientific Officer at ICx Biosystems from 2003 to 2009. The biotechnology firm specialized in developing advanced detection technologies for biodefense, cancer, and prenatal diagnostics. His work at ICx Biosystems contributed to significant advancements in these critical fields.

Contribution to Rosetta Inpharmatics

From 1998 to 2003, Daniel Shoemaker was one of the founding scientists at Rosetta Inpharmatics. The company created a novel microarray platform and a suite of bioinformatics tools for analyzing large genomic data sets. His contributions helped usher in new methodologies for genomic analysis, leading to the acquisition of Rosetta Inpharmatics by Merck.

Senior Director of Genomics at Merck

Following the acquisition of Rosetta Inpharmatics by Merck, Daniel Shoemaker took on the role of Senior Director of Genomics. In this role, he oversaw genomic research efforts, further advancing Merck's capabilities in this important area of biotechnology.

People similar to Daniel Shoemaker